Kidney Cancer Drugs Market

Your Catalyst To a Lucrative Business
Kidney Cancer Drugs Market Share, Size, Analysis, Growth,
Trends and Forecasts to 2025 | Hexa Research
" Global kidney cancer drugs market is expected to
grow at a healthy rate during the forecast period.”
The global Kidney Cancer Drugs Market is expected to grow at a healthy rate during the forecast period. Renal
Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2%
of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure
from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced
by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced
stage of disease progression.
Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune
modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to
cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer
when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness
drives for early detection. This factor is anticipated to bode well for market over the forecast period.
Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of
smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to
several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate
among patients who are mostly diagnosed with RCC during routine checkups for some other medical
Browse Details of Report @
Follow Us:
Your Catalyst To a Lucrative Business
The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle
influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to
chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer
medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel
demand for these medicines in the years to come.
Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market
over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting
product demand. Kidney cancer medicines are one of the life protracting treatment options available for
patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is
expected to be higher in developed countries compared to developing regions. This factor is expected to impel
demand for these medicines from regions like North America and Europe.
However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result,
generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct
market development in the forthcoming years.
Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta
(Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel
(Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine
types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the
forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as
Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in
the years to come.
North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other
kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This
factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is
estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease
prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive
regional growth in the forthcoming years.
The global market is highly consolidated and displays high competition among key participants. Major
pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La
Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting
strategies like collaborations, new product launches, business expansions, and innovation to upho ld their
market share.
Browse Related Category Market Reports @
Follow Us:
Your Catalyst To a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: [email protected]
Website -
Follow Us:

The global kidney cancer drugs market is expected to grow at a healthy rate during the forecast period.